Concordance among gene-expression-based predictors for breast cancer
- PMID: 16899776
- DOI: 10.1056/NEJMoa052933
Concordance among gene-expression-based predictors for breast cancer
Abstract
Background: Gene-expression-profiling studies of primary breast tumors performed by different laboratories have resulted in the identification of a number of distinct prognostic profiles, or gene sets, with little overlap in terms of gene identity.
Methods: To compare the predictions derived from these gene sets for individual samples, we obtained a single data set of 295 samples and applied five gene-expression-based models: intrinsic subtypes, 70-gene profile, wound response, recurrence score, and the two-gene ratio (for patients who had been treated with tamoxifen).
Results: We found that most models had high rates of concordance in their outcome predictions for the individual samples. In particular, almost all tumors identified as having an intrinsic subtype of basal-like, HER2-positive and estrogen-receptor-negative, or luminal B (associated with a poor prognosis) were also classified as having a poor 70-gene profile, activated wound response, and high recurrence score. The 70-gene and recurrence-score models, which are beginning to be used in the clinical setting, showed 77 to 81 percent agreement in outcome classification.
Conclusions: Even though different gene sets were used for prognostication in patients with breast cancer, four of the five tested showed significant agreement in the outcome predictions for individual patients and are probably tracking a common set of biologic phenotypes.
Copyright 2006 Massachusetts Medical Society.
Comment in
-
Molecular signatures predict outcomes of breast cancer.N Engl J Med. 2006 Aug 10;355(6):615-7. doi: 10.1056/NEJMe068145. N Engl J Med. 2006. PMID: 16899783 No abstract available.
-
Gene-expression-based predictors for breast cancer.N Engl J Med. 2007 Feb 15;356(7):752; author reply 752-3. doi: 10.1056/NEJMc062416. N Engl J Med. 2007. PMID: 17301312 No abstract available.
Similar articles
-
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15. J Clin Oncol. 2010. PMID: 20231686
-
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.J Clin Oncol. 2006 Apr 10;24(11):1656-64. doi: 10.1200/JCO.2005.03.2755. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505416
-
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.J Clin Oncol. 2007 Apr 1;25(10):1239-46. doi: 10.1200/JCO.2006.07.1522. J Clin Oncol. 2007. PMID: 17401012
-
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial.
-
Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.Semin Radiat Oncol. 2009 Oct;19(4):204-10. doi: 10.1016/j.semradonc.2009.05.004. Semin Radiat Oncol. 2009. PMID: 19732684 Review.
Cited by
-
Study of integrated heterogeneous data reveals prognostic power of gene expression for breast cancer survival.PLoS One. 2015 Feb 27;10(2):e0117658. doi: 10.1371/journal.pone.0117658. eCollection 2015. PLoS One. 2015. PMID: 25723490 Free PMC article.
-
Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.BMC Vet Res. 2021 May 25;17(1):197. doi: 10.1186/s12917-021-02901-1. BMC Vet Res. 2021. PMID: 34034728 Free PMC article.
-
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.PLoS One. 2012;7(9):e44225. doi: 10.1371/journal.pone.0044225. Epub 2012 Sep 7. PLoS One. 2012. PMID: 22970185 Free PMC article.
-
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.Clin Cancer Res. 2016 Dec 1;22(23):5755-5764. doi: 10.1158/1078-0432.CCR-16-0148. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185372 Free PMC article. Clinical Trial.
-
A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients.Front Oncol. 2021 Mar 17;11:645853. doi: 10.3389/fonc.2021.645853. eCollection 2021. Front Oncol. 2021. PMID: 33816299 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous